Skip to main content

Table 1 Clinical characteristics and risk factors for 30-day mortality in patients with CRE BSI

From: Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options

 

All Patients

(n = 94)

Survivors

(n = 67)

Non-survivors

(n = 27)

P value

Sex

   

0.530

Male

58 (61.7)

40 (69.0)

18 (31.0)

 

Female

36 (38.3)

27 (75.0)

9 (25.0)

 

Age (years), median (IQR)

38 (25–49)

38 (27–49)

33 (18–49)

0.254

Charlson comorbidity score

   

0.205

2

80 (85.1)

59 (73.8)

21 (26.3)

 

3–4

14 (14.9)

8 (57.1)

6 (42.9)

 

Underlying hematological disease

   

< 0.001

Standard-risk group

36 (38.3)

34 (94.4)

2 (5.6)

 

High-risk group

58 (61.7)

33 (56.9)

25 (43.1)

 

Received HSCT

   

0.678

Yes

20 (21.3)

15 (75.0)

5 (25.0)

 

No

74 (78.7)

52 (70.3)

22 (29.7)

 

CRE isolates

   

0.052

Escherichia coli

48 (51.1)

35 (72.9)

13 (27.1)

 

Klebsiella pneumoniae

36 (38.3)

22 (61.1)

14 (38.9)

 

Others

10 (10.6)

10 (100)

0 (0)

 

MDRO carriage/infection

   

0.968

Yes

56 (59.6)

40 (71.4)

16 (28.6)

 

No

38 (40.4)

27 (71.1)

11 (28.9)

 

Meropenem MICs (mg/L)

   

0.806

> 8

78 (83.0)

11 (68.8)

5 (31.2)

 

≤ 8

16 (17.0)

56 (71.8)

22 (28.2)

 

Length of neutropenia

   

0.012

≥ 14 days

68 (76.4)

46 (67.6)

22 (32.4)

 

< 14 days

21 (23.6)

20 (95.2)

1 (4.8)

 

Mucositis

   

0.188

Yes

29 (30.9)

18 (62.1)

11 (37.9)

 

No

65 (69.1)

49 (75.4)

16 (24.6)

 

Pitt bacteremia score

   

0.002

≥ 2

31 (33.3)

16 (51.6)

15 (48.4)

 

< 2

62 (66.7)

51 (82.3)

11 (17.7)

 

Septic shock

   

< 0.001

Yes

15 (16)

4 (26.7)

11 (73.3)

 

No

79 (84)

63 (79.7)

16 (20.3)

 

Co-infections

    

Pulmonary infection

34 (36.2)

17 (25.4)

17 (63.0)

0.001

Gastroenteritis

15 (16.0)

10 (14.9)

5 (18.5)

0.667

Perianal infection

14 (14.9)

12 (17.9)

2 (7.4)

0.196

others

16 (17.0)

9 (13.4)

7 (25.9)

0.145

  1. IQR, interquartile range; HSCT, hematopoietic stem cell transplantation; MDRO, multidrug-resistant organism